Amazon Hurricane Heading Towards Indian Pharma?
Think Amazon, think disruption, and that’s exactly what could be in store if the online retail juggernaut goes through with its rumored plans to invest in MedPlus, India’s second largest retail pharmacy chain. A deal could also have ramifications for private equity/venture capital activity in the Indian pharmacy space, say some experts.
You may also be interested in...
2019 promises to be action-packed for Indian firms as they stay hungry for M&A and on course to transition to a more innovation-led play. But election year surprises in India, rising patient awareness, and the entry of non-traditional players like Amazon could well up the variable quotient for pharma, industry pundits tell Scrip.
2018 may not be smooth sailing for Indian firms, going by the predictions of top industry pundits. Possible upheavals on the domestic market, dynamics that demand a hawk eye on expenses and gains but also pressures as a result of FDA reforms suggest that a relatively tough year may be in store.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.